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Abstract
Despite the success of colonoscopy screening, colorectal cancer (CRC) remains one of the most 
common and deadly cancers, and CRC incidence is rising in some countries where screening is 
not routine and populations have recently switched from traditional diets to western diets. Diet and 
energy balance influence CRC by multiple mechanisms. They modulate the composition and 
function of gut microbiota, which have a prodigious metabolic capacity and can produce 
oncometabolites or tumor-suppressive metabolites depending, in part, on which dietary factors and 
digestive components are present in the GI tract. Gut microbiota also have a profound effect on 
immune cells in the lamina propria, which influences inflammation and subsequently CRC. 
Nutrient availability, which is an outcome of diet and energy balance, determines the abundance of 
certain energy metabolites that are essential co-factors for epigenetic enzymes and therefore 
impinges upon epigenetic regulation of gene expression. Aberrant epigenetic marks accumulate 
during CRC, and epimutations that are selected for drive tumorigenesis by causing transcriptome 
profiles to diverge from the cell of origin. In some instances, the above mechanisms are 
intertwined as exemplified by dietary fiber being metabolized by colonic bacteria into butyrate, 
which is both a short-chain fatty acid (SCFA) and a histone deacetylase (HDAC) inhibitor that 
epigenetically upregulates tumor-suppressor genes in CRC cells and anti-inflammatory genes in 
immune cells.
Keywords
Colorectal cancer; Gut microbiota; Oncometabolites; Tumor-suppressive metabolites; 
Inflammation; Warburg effect; Butyrate; Epigenetics; Histone acetylation
Influence of Diet on Colorectal Cancer
Colorectal cancer (CRC) is among the three most diagnosed and deadly cancers in both men 
and women in the USA as well as globally (1, 2). It is estimated that 132,700 new CRC 
cases were diagnosed in the USA during 2015 along with 49,700 associated deaths (2). 
However, the good news is that these figures have been decreasing ~3% per year over the 
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past decade in the USA (2). This downward trend is attributed to more frequent colonoscopy 
screening leading to the early detection and removal of pre-cancerous adenomas (3). 
Although the CRC burden is stable or decreasing in the USA and other western countries, 
this is not the case elsewhere (4). In contrast, CRC incidence and mortality have been 
increasing in developing countries and newly industrialized countries such as China due to 
their populations adopting western diets and lifestyles. CRC rates have doubled in some 
Asian and Eastern European countries since the mid-1970s (4).
Notwithstanding the success of colonoscopy screening, the CRC burden could be diminished 
by ~50% via diet, physical activity, and weight management (5). Numerous prospective-
cohort epidemiology studies have identified specific dietary and lifestyle factors that either 
promote or protect against CRC (Table 1) (5). For example, consumption of red meat and 
animal fats increase risk, whereas dietary fiber decreases risk. Energy balance is particularly 
important, and the obesity epidemic will undoubtedly have a significant adverse impact. Due 
to the Warburg effect, cancer cells become addicted to glucose: glucose transporters 
(GLUTs) are upregulated, glucose uptake is ≥10-fold, and aerobic glycolysis is utilized to 
generate ATP in a relatively inefficient manner (6). Therefore, the high blood glucose levels 
that occur in obese individuals with metabolic syndrome, type-2 diabetes, and even pre-
diabetic insulin resistance represent a tumor-permissive environment that can metabolically 
drive cancer. This idea is supported by the clinical success of metformin, a diabetes drug that 
lowers blood glucose levels, for the prevention and treatment of CRC and other cancers (7, 
8).
A positive energy balance (i.e., caloric intake > energy expenditure) that results in insulin 
resistance usually leads to elevated circulating levels of insulin and insulin-like growth 
hormone (IGF) (also known as hyperinsulinemia) as a compensatory mechanism. Increased 
insulin or IGF in hyperinsulinemia can drive cancer by binding to their cognate tyrosine 
kinase receptors and upregulating pro-oncogenic growth factor signaling pathways such as 
PI3K-AKT-mTOR (which can trigger MDM2 degradation of p53) and RAS-RAF-ERK 
(which can upregulate c-MYC expression) that stimulate cell growth and proliferation while 
inhibiting apoptosis (9, 10). Although CRC incidence has reached a plateau and gone down 
over the past decade(s) in the USA, there has been a concomitant rise in early-onset cases 
(e.g., diagnosis <50 years of age, which is prior to the age of routine colonoscopy screening) 
not associated with familial cancer syndromes such as FAP and HNPCC/Lynch syndrome 
(4, 11), and this trend is believed to be due to the increased prevalence of obesity. One 
possibility is that obesity-induced activation of RAS-RAF-ERK and PI3K-AKT-mTOR 
signaling in both young and old individuals accelerates carcinogenesis by substituting for 
somatic mutations that genetically activate these same pathways but which occur over a 
longer timeframe (12). This idea is compatible with KRAS, BRAF, and p53 mutations being 
the primary drivers of CRC progression and which are mutated more frequently than any 
other gene except APC (which usually initiates CRC) (13). Indeed, when CRC exome 
sequencing data from The Cancer Genome Atlas (TCGA) were stratified according to body 
mass index (BMI), obese individuals were reported to have a lower frequency of mutations 
for driver genes in general and for KRAS in particular (12). These findings support the idea 
that the selective pressure for driver mutations is lost when the corresponding genes and 
genetic pathways are deregulated via perturbation of their cellular milieu.
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In addition to relatively direct effects of diet on CRC, as mentioned above, diet is likely to 
influence CRC indirectly by modulating the composition and metabolism of gut microbiota 
and by epigenetically regulating gene expression. These topics are covered in the next two 
sections.
Influence of Gut Microbiota on Colorectal Cancer
Our bodies harbor a huge number (≥1014) of microbial cells, and the lumen of the colon has 
the highest microbial density by far (14). Microbiome studies, which utilize metagenomic 
DNA sequencing approaches to catalog the diversity and abundance of bacteria in fecal 
samples or mucosal biopsies obtained by endoscopy, have demonstrated that the human gut 
microbiome is relatively stable in individuals over time except in the case of certain events 
such as food poisoning/infection or international travel (15, 16). This likely reflects the 
hegemony of long-term dietary patterns on our gut microbiome (17). Nevertheless, our gut 
microbiome does respond to short-term dietary interventions. For example, switching from a 
traditional diet that is high in plant polysaccharides including fiber and low in animal fat and 
processed sugar to a reciprocal western diet that is low in plant polysaccharides/fiber and 
high in animal fat and processed sugar (including the pervasiveness of high-fructose corn 
syrup) leads to a rapid shift (within a day) in the microbiome (18–20). Many observed 
changes are as expected and reflect natural selection or a similar process where certain 
bacterial clades or genera grow at the expense of others in response to an altered 
environment. For instance, the aforementioned dietary switch to a western diet resulted in a 
bloom of bile-tolerant bacteria such as Bilophilia and Bacteroides with a concomitant 
decline in Firmicutes such as Roseburia that metabolize plant polysaccharides (20). 
However, short-term dietary interventions tend to transiently affect the gut microbiome and 
are usually not maintained following a return to the long-term diet (17). For this reason, 
short-term dietary interventions are unlikely to be successful for reshaping the microbiome 
in a stable manner for CRC prevention as is known to be the case for weight loss. Finally, it 
should be noted that our knowledge is limited because diet probably has a much larger effect 
on the microbiome’s transcriptional output (i.e., the metatranscriptome) and metabolite 
production (i.e., metabolome) than the relative abundance of specific bacteria (21–24). 
These topics are currently being investigated and should further increase our understanding 
of the relationship between diet and the function of gut microbiota.
It is noteworthy that dietary fiber and red meat plus animal fats have particularly strong 
effects on microbiome structure because they have significant, diametrically opposed effects 
on CRC risk (as discussed above and listed in Table 1). This correlation supports the idea 
that long-term changes in our diet influence CRC via microbiome changes. Indeed, human 
microbiome studies have demonstrated that the bacterial community structure of the gut is 
often perturbed in CRC and in other disease states such as inflammatory bowel disease 
(IBD). Bacterial diversity is diminished in both CRC and IBD, and this is referred to as 
dysbiosis. Human microbiome studies have also identified significant changes in the 
abundance of specific bacteria in CRC cases compared to controls. For example, Escherichia 
coli strains containing a pks pathogenicity island, Fusobacterium nucleatum, and 
Providencia are overrepresented in CRC cases, whereas Lactobacillus and butyrate-
producing bacteria such as Roseburia and Fecalibacterium are underrepresented (25, 26). 
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However, metagenomic sequence data cannot establish causality because a particular 
microbiome change could be either a cause or a consequence of CRC. To overcome this 
limitation, germfree mouse models of CRC are colonized with one or more specific bacteria 
either enriched or depleted in human CRC cases while being maintained in gnotobiotic 
isolators (25). When these “humanized” mouse models have significantly different tumor 
burdens, Koch’s postulates are virtually fulfilled and causality is demonstrated. The bacteria 
can also be genetically modified in these studies as was done to demonstrate that the pks 
pathogenicity island, which encodes a toxin (colibactin) that induces DNA damage in the 
colonic epithelium, is responsible for the contribution of E. coli to CRC (27).
Gut microbiota can either promote or protect against CRC by several mechanisms. First, 
dietary and digestive factors are metabolized by microbiota into putative oncometabolites 
and tumor-suppressive metabolites (Figure 1) (28). To exemplify the promotion of 
carcinogenesis, red meat and bile acids produced in response to the digestion of animal fats 
are converted by gut bacteria into hydrogen sulfide and secondary bile acids such as DCA, 
respectively. To exemplify cancer prevention, plant-based polyphenols and fiber are 
converted by gut microbiota into equol or urolithins and short-chain fatty acids (SCFAs) 
such as butyrate, respectively. Second, gut microbiota affect intraepithelial lymphocytes and 
immune cells in the lamina propria to modulate inflammatory responses (Figure 1). 
Inflammation is recognized as a hallmark of cancer (29), and CRC is particularly sensitive to 
inflammation considering that aspirin and NSAIDs diminish CRC risk to a larger extent than 
any other cancer (30, 31). In further support of the microbiota-inflammation-CRC link, 
microbiota play a key role in IBD, and IBD patients with colonic inflammation have a 2–10 
fold increased risk of CRC (32). In addition to directly affecting immune cells, the gut 
microbiota can influence the permeability of the colonic epithelium and barrier function 
(Figure 1), which, in turn, determines the extent to which luminal bacteria and bacterial 
antigens such as LPS and flagellin come into contact with immune cells. Furthermore, 
obesity is associated with increased intestinal permeability (which may involve microbiota) 
and inflammation (33, 34), which strongly suggests that it exacerbates CRC independent of 
energy balance.
Gut microbiota can also influence CRC and other cancers indirectly by affecting energy 
balance. The gut microbiome changes in response to diet, as discussed above, and the 
Bacteroides-to-Firmicutes ratio is shifted downward in obese individuals (35). The “obese 
microbiota” are enriched for genes involved in carbohydrate and lipid metabolism, which 
enables more calories to be extracted from energy-rich diets (18). To address the issue of 
cause versus effect, fecal microbiota from obese versus lean and normal versus 
malnourished donors have been transplanted into germfree mice in gnotobiotic isolators. 
Comparisons of FMT outcomes support the idea that gut microbiota modulate energy 
balance and adiposity (36–38). The gut microbiome will affect many specific components of 
our diets including additives and preservatives in processed foods. One example is the 
central role of our gut microbiota in the observation that artificial sweeteners (e.g., diet soda) 
induce glucose intolerance (39). Another example is emulsifiers such as 
carboxymethylcellulose and polsorbate-80 that can induce low-grade inflammation, obesity/
metabolic syndrome, and colitis in gnotobiotic mouse models (40).
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Finally, it should be emphasized that gut microbiota are not only relevant for cancer 
prevention but are also emerging targets for therapy. For example, irinotecan (also known as 
camptothecin 11) is a topoisomerase I inhibitor commonly used as a chemotherapeutic agent 
for the treatment of CRC. As part of normal drug metabolism, it is inactivated via 
glucuronidation in the liver and excreted through the GI tract, but bacterial β-glucuronidases 
cleave the glucuronide group as an energy source, which reactivates the active 
chemotherapeutic in the gut to harm or kill rapidly dividing intestinal epithelial cells and 
cause severe GI distress including diarrhea (41). Antibiotics does not represent a preferred 
treatment option because the indiscriminate killing of bacteria can be deleterious (including 
the onset of C. difficile infections) so pharmacologic inhibitors of bacterial β-glucuronidases 
were developed. Oral administration of these inhibitors is effective at alleviating the GI 
toxicity of irinotecan in mouse models (41), and this approach may allow the dose or 
duration of irinotecan to be ramped up in human CRC patients. One might expect these 
inhibitors to be effective in combination with additional drugs that are glucuronidated in the 
liver and reactivated by bacterial β-glucuronidases in the gut including other 
chemotherapeutics and NSAIDs (which cause intestinal bleeding when reactivated in the 
intestine). Another good example comes from immunotherapy, which is currently the 
vanguard of anti-cancer therapy. Antibodies that inhibit either CTLA-4 or PD-L1 have 
shown particular promise by triggering a checkpoint blockade that unleashes a robust 
immune response against cancer cells. Interestingly, the efficacy of anti-CTLA4 and - PD-L1 
treatments is dependent on the composition of the patients’ gut microbiota and its ability to 
induce the maturation of dendritic cells followed by a robust response from tumor 
infiltrating T cells (42, 43). In addition to FMTs, specific bacteria were identified (e.g., 
Bifidobacterium and Bacteroides such as B. fragilis), and “therapeutic feeding” of one these 
bacteria improved the efficacy of immunotherapy in a mouse model (42, 43). The studies 
cited here focused on melanomas, but immunotherapy is being evaluated for the treatment of 
other cancers including CRC, and probiotics clearly represent a potential adjuvant treatment.
Influence of Epigenetics on Colorectal Cancer
Tumorigenesis is driven not only by mutations but also by dysregulated epigenomic 
alterations that cause the transcriptome profile of a cancer cell to diverge from the cell of 
origin (44). This process includes the inappropriate addition or removal of acetyl and methyl 
marks at specific histone residues. These histone modifications often lead to a corresponding 
gain or loss of DNA methylation at CpG dinucleotides, which can stably maintain the 
altered epigenomic state through numerous cell divisions (45, 46). Aberrant epigenetic 
modifications, which are sometimes referred to as “epimutations”, occur at promoters or 
enhancers of tumor-suppressor genes and proto-oncogenes and are often selected for during 
tumorigenesis. Epimutations are well documented in CRC where many genes (e.g., APC, 
LKB1, GATA4, p16INK4a, MLH1) and genetic pathways are common targets (47). 
Epigenetic inactivation of MLH1 and other mismatch repair genes results in a dramatic 
increase in mutations within the tumor (i.e., a mutator phenotype manifest by microsatellite 
instability), which demonstrates that there can be a causal relationship between epimutations 
and mutation burdens that contribute to genomic instability. Histone 3 lysine 9 acetylation 
(H3K9ac) and H3K27ac are particularly relevant because these marks are highly enriched at 
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active gene promoters and enhancers, respectively (29, 48, 49). Furthermore, H3K27ac has 
been used (along with H3K4me1) to define variant enhancer loci (VEL) that are 
differentially acetylated/activated in normal colonic tissue versus CRC samples in humans 
(48). H3K9 and H3K27 residues are also noteworthy because they can be modified by either 
active acetyl marks or inactive methyl marks (with H3K27 methylation being catalyzed by 
the EZH2 component of PRC2), and this yin-yang relationship is often in a state of flux. 
Histone acetylation is regulated by the balance between histone acetyltransfereases (HATs) 
and histone deacetylases (HDACs), which add and remove acetyl groups, respectively. Non-
histone proteins including p53 are also direct targets that can be relevant. An imbalance in 
HAT and HDAC enzymatic activities underlies a variety of cancers. For example, HDACs 1, 
2, 3, and 6 are recurrently upregulated in CRC and other cancers, and genetic knockdown of 
these genes in tumor-derived cell lines induces cell-cycle arrest and apoptosis (50). HDAC 
inhibitors are being developed by biotechnology and pharmaceutical companies for anti-
cancer chemotherapy, and vorinostat (also known as SAHA) and romidepsin have already 
been approved by the FDA (albeit for the treatment of lymphomas rather than CRC) (50).
Epigenetics also represents a mechanism that links diet and nutrient availability with 
regulation of gene expression to maintain homeostasis. The basis for this mechanistic link is 
the fact that most epigenetic enzymes utilize energy metabolites or redox factors as essential 
co-factors (51). DNA methyltransferases and histone methyltransferases utilize S-
adenosylmethionine, a product of 1-carbon metabolism, as the methyl-group donor; histone 
acetyltransferases (HATs) utilize acetyl-CoA, a central component of energy metabolism, as 
the acetyl-group donor; class III HDACs (also known as sirtuins) are dependent on the redox 
factor NAD+; TET and JmjC dioxygenases require the TCA cycle intermediate α-
ketoglutarate to demethylate DNA and histones, respectively. In certain cases, diet 
influences gene expression to an extent that influences phenotypic outcomes and disease 
states. For example, dietary supplementation of 1-carbon cycle micronutrients (e.g., folate, 
vitamin B12, choline) influences coat color, obesity, and tumorigenesis in genetically 
identical viable-yellow mice (51–53). And children conceived during the Dutch hunger 
winter of 1944–1945 and other famines have had increased incidence of schizophrenia and 
other ailments later in life, which in some cases have been associated with altered CpG 
methylation profiles of target genes such as IGF [albeit in peripheral blood cells, which may 
or may not be representative of the diseased tissue (e.g., CNS) or relevant to the disease state 
(e.g., complex behaviors)] (54). There is precedent for energy metabolites functioning in 
human cancer. The oncometabolite 2-hydroxyglutarate, which arises because of neomorphic 
IDH mutations in lymphomas and gliomas, is sufficient to promote neoplasia (55). It is 
generated in cancer cells at the expense α-ketoglutarate and inhibits both TETs and JmjC 
enzymes to alter DNA and histone methylation (55). The TCA cycle intermediates succinate 
and fumarate also function in this capacity in response to oncogenic mutations in genes 
encoding TCA cycle enzymes (56). Finally, considering the prodigious metabolic capacity 
of the gut microbiome, bacteria will likely convert dietary factors and digestive components 
into metabolites that regulate epigenetics in cancer. A recent comparison of colonic 
epithelial cells from germfree and conventional mice revealed surprisingly few differences in 
chromatin accessibility (57), but this does not rule out other possible differences such as 
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local histone modifications. Although our knowledge in this area is limited, the next section 
provides a proof of principle for a bacterial metabolite in histone acetylation.
The fiber-microbiota-butyrate axis in epigenetics and CRC prevention
Dietary fiber is defined as “the edible part of plants or their extracts, or analogous 
carbohydrates, that are resistant to digestion and absorption in the small intestine, but are 
utilized after partial or complete fermentation in the large intestine by resident microbiota” 
(58). Fiber includes polysaccharides (e.g., resistant starch, cellulose, hemicellulose, pectins, 
and gums), oligosaccharides, and lignins. Although fiber has been investigated for many 
years, it continues to be studied and provide new insights. A particularly strong study was 
recently published in which native Africans and African Americans participated in a 2-week 
dietary intervention (59). Native Africans, who have a low rate of CRC (<5 per 100,000), 
switched from their traditional high-fiber diets to low-fiber western diets, while African 
Americans (who have a >10-fold higher rate at 65 per 100,000) switched from their western 
diets to high-fiber, traditional diets. The dietary changes affected the gut microbiome and led 
to reciprocal changes in metabolites such as SCFAs including butyrate and mucosal 
biomarkers of cancer risk (59).
Increased fiber consumption has the potential to decrease CRC risk by two general 
mechanisms that are not mutually exclusive. First, insoluble fiber speeds colonic transit and 
may diminish the exposure of colonic epithelial cells to ingested carcinogens such as 
heterocyclic amines from charred meat (Figure 2). Second, soluble fiber is fermented by 
certain clades of bacteria into butyrate and other potentially beneficial metabolites (Figure 
2). Although dietary fiber is generally believed to diminish CRC risk, there has been a lack 
of consensus because of conflicting results from prospective-cohort epidemiology studies 
(60). These studies have been reliant on self-report questionnaires to track participants’ 
dietary habits for ~3 years so compliance is a concern that probably hinders reproducibility. 
Another limitation is that meta-analyses must be conducted carefully because different 
studies utilize different fiber sources, which are metabolized to different extents and yield 
different levels of metabolites. ≥5 microbiome studies have reported a significant decrease in 
butyrate-producing bacteria in human CRC cases compared to controls, but it is not clear 
whether this is a cause or a consequence of the disease (25, 61). Although most research 
using mouse models support the idea that butyrate is tumor suppressive (25, 62), a recent 
study suggested that butyrate promotes CRC (63). This study utilized a mouse model with 
impaired mismatch repair, but it is not clear whether this is sufficient to reconcile the 
contradictory findings (64).
To investigate dietary fiber and butyrate in a highly controlled manner, a mouse model of 
CRC was polyassociated with several bacteria in a gnotobiotic isolator and provided control 
or high-fiber diets that were otherwise isocaloric and virtually identical (65, 66). The high-
fiber diet was provided from weaning (prior to tumor initiation) until the time of sacrifice 
and had a protective effect in mice colonized with a wild-type butyrate-producing bacterium 
but not in mice lacking a butyrate producer (Figure 3). The same mice colonized with a 
mutant strain of the butyrate-producing bacterium, which harbors a small deletion in the 
butyryl CoA synthesis operon and produces diminished levels of butyrate, had an attenuated 
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protective effect with an intermediate tumor burden (Figure 3). Furthermore, mice that 
completely lacked butyrate-producing bacteria but were provided a diet fortified with 
butyrate had a lower tumor burden than any of the other treatment groups (Figure 3). This is 
arguably the most convincing evidence that butyrate is a causal factor because it 
demonstrates that the fiber-microbiota tumor-suppressive effect can be recapitulated by 
exogenous butyrate. Future studies will need to be performed where the high-fiber, 
“butyrogenic” diet is provided after tumorigenesis is initiated to determine whether it is still 
protective.
The above study also explored the molecular mechanism of how butyrate functions as a 
dietary- and microbiota-derived tumor-suppressive metabolite (65). Unlike most cell types in 
the body, which utilize glucose as their primary energy source, normal colonocytes rely on 
butyrate for ~60–70% of their energy (67–69). As a fatty acid, butyrate undergoes β-
oxidation in the mitochondria (67), and this supports energy homeostasis necessary for the 
rapid cell proliferation of the colonic epithelium (Figure 2). The colonic and small intestinal 
epithelium arguably turn over faster than any other tissue in the body (every ≤7 days) with 
rapid cell proliferation near the base of the crypt counterbalanced with apoptosis near the 
lumen. In contrast, CRC cells (and cancer cells in general) undergo the Warburg effect and 
switch to glucose utilization and aerobic glycolysis (6) (Figure 2). As a result of this 
metabolic shift, butyrate is not metabolized in the mitochondria of CRC cells to the same 
extent and accumulates in the nucleus where it functions as an HDAC inhibitor to 
epigenetically regulate gene expression (65, 70) (Figure 2). In support of this model, 
butyrate (detected by LC-MS) and global histone acetylation levels (detected by 
immunohistochemistry and western blots) were elevated in tumors from mice that were 
colonized with the wild-type butyrate producer and provided a high-fiber diet, and this 
correlated with a lower tumor burden (Figure 3). Butyrate is a well-established HDAC 
inhibitor (71, 72), and butyrate target genes in tumors from mice provided a high-fiber diet 
included Fas and p21, which promote apoptosis and inhibit cell-cycle progression, 
respectively. This finding is compatible with the diminished tumor burden in these mice and 
the idea that butyrate is a tumor-suppressive metabolite.
The tumor-suppressive mechanism(s) is probably more complicated than described above. 
Insoluble fibers such as cellulose are not fermented by gut microbiota and speed colonic 
transit as mentioned above. Soluble fibers are fermented into SCFAs other than butyrate, 
such as acetate and propionate, and these or other metabolites could also contribute to CRC 
prevention. Propionate is also an HDAC inhibitor although it is not as potent as butyrate and 
has broader bioavailability with less accumulation in colonocytes (73). Finally, butyrate is a 
pleiotropic molecule and may prevent cancer via additional mechanisms. In addition to 
functioning as an HDAC inhibitor, it can signal through certain G protein coupled receptors 
(74, 75). Butyrate may diminish tumorigenesis by attenuating inflammation. Butyrate 
enemas strongly ameliorate colonic inflammation associated with inflammatory bowel 
diseases (IBD) such as colitis and Crohn’s disease in both rodent models and human patients 
(72). This is noteworthy because colitis patients have up to a 10-fold increased risk of CRC 
as mentioned above (32, 76), which is consistent with the link between inflammation and 
cancer (29). A series of recent studies demonstrate that butyrate activates FoxP3 expression 
in naïve CD4+ T cells and dendritic cells and induces the differentiation and expansion of 
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immunosuppressive regulatory T (Treg) cells (77–84). Another recent study demonstrates 
that butyrate downregulates the production of pro-inflammatory cytokines by intestinal 
macrophages (85). Butyrate is also known to affect colonocyte permeability and barrier 
function (86, 87). In other words, butyrate participates in each functional category illustrated 
in Figure 1. This example demonstrates that diet and gut microbiota can interact to influence 
multiple mechanisms relevant to cancer including epigenetics and inflammation.
Lack of consensus and unresolved issues regarding fiber and the gut 
microbiome
Diet may have a more modest effect on the composition and function of gut microbiota in 
humans than mice, and there is currently a lack of consensus regarding the effect size in 
humans. For example, a recently published study comparing vegans to omnivores in the 
USA, which included a 10-day dietary intervention trial, detected relatively subtle 
differences in the composition of gut microbiota (88). Furthermore, butyrate and other SCFA 
levels were not significantly different between the two groups although fiber intake was 
higher in vegans. These findings are different than what has been observed in Native 
Africans that still rely on a traditional, high-fiber diet (59). One possibility is that the 
capacity of an individual’s microbiome to ferment fiber into SCFAs might become 
constrained after a prolonged (i.e., years or lifetime) low-fiber diet. One might also expect 
transgenerational effects because an individual “inherits” their microbiota from their mother 
at birth and usually adopts a similar diet. Therefore, a diminished capacity to ferment fiber 
into SCFAs could be amplified after two or more generations of low-fiber consumption. This 
idea is supported by another recent study that provided a low-fiber diet to mice colonized 
with human microbiota and observed diminished microbiome diversity (89). Interestingly, 
this microbiome change was initially reversible (within one generation) but became 
progressively irreversible with diet-induced extinctions after several generations. In a 
situation like this, prebiotics (e.g., a high-fiber diet) will not be sufficient, and probiotics will 
be necessary to re-introduce specific gut bacteria into the gut ecosystem to produce SCFAs. 
In the absence of the appropriate diet (e.g., low-fiber diet), however, it might be necessary to 
develop something analogous to a gene-drive system (as has been proposed for eradicating 
malaria) to select for the re-introduced beneficial bacteria.
Other diet- and microbial-derived metabolites implicated in cancer 
prevention
The previously cited study identified 92 out of 361 metabolites (25%) that had significantly 
different concentrations in plasma from vegans versus omnivores (88). Although these 
changes did not correlate with microbiome changes, another study utilizing germfree mice 
estimated that 10% of plasma metabolites are influenced by microbiota (90). Therefore, it 
stands to reason that many diet- and microbe-derived metabolites will influence colorectal 
cancer and other cancers.
Dietary polyphenols, which include flavonoids (e.g., quercetin and kaempferol), phenolic 
acids, anthrocyanins, and lignins present in tea, wine, fruits, nuts, and vegetables, have 
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received extensive attention because of their chemoprotective effects in mouse models and 
human epidemiology studies. Resveratrol has probably received the most attention because 
it is a caloric-restriction mimetic that is pleiotropic and benefits health in multiple ways. 
However, it is not the best example for being metabolized by gut microbiota. In contrast, 
ellagic acid is a polyphenol present in certain berries and nuts that is an anti-oxidant with 
cancer-preventive properties. Ellagic acid is metabolized by colonic microbiota into 
urolithins that have pro-estrogenic and anti-estrogenic activities in a context-dependent 
manner (91). Urolithins can also downregulate COX-2 to lower prostaglandin production 
and inflammation so the anti-cancer effects apparently involve multiple pathways. Another 
polyphenol is daidzein, which is a soy-based isoflavone metabolized by gut microbiota into 
equol. Some epidemiologic studies have reported correlations between equol or equol-
producing bacteria and diminished breast cancer risk in women and diminished prostate 
cancer risk in men. However, these correlations have been observed in Asian populations but 
not European populations (91). It is not clear whether these ethnic disparities are due to 
differences in genetics, microbiota, or diet (e.g., soy consumption), and more work will be 
required to strengthen the link between equol and cancer prevention. Interestingly, only 30–
40% of westerners are able to produce equol, whereas 60–70% of Asians are able to do so 
(91). Although the reason for this difference is not understood, it could be due, in part, to the 
relative abundance of specific bacteria. In the previously cited study, only 40% of the vegans 
had detectable equol in their plasma despite similar levels of isoflavone intake (88). This 
suggests that long-term diet and transgenerational effects may lead to irrevocable changes in 
the microbiome and metabolome that are relevant to both fiber/SCFA- and soy isoflavone/
equol-mediated cancer susceptibility.
Cruciferous vegetables such as broccoli and cabbage contain high levels of glucosinolates. 
When these vegetables are uncooked and either chopped or chewed, plant-derived 
myrosinases convert the glucosinolates to isothiocyanates (ITC) such as sulforaphane, which 
is an HDAC inhibitor like butyrate, that have anti-carcinogenic properties in cell lines and 
mouse models and might diminish human cancer risk. The evidence is strongest for 
colorectal, lung, breast, prostate, and prostate although the epidemiology results are mixed. 
However, cruciferous vegetables are usually cooked. Although heat denatures the plant-
derived myrosinases, bacteria-derived thioglucosidases convert glucosinolates into ITC in 
the gut to exert their beneficial effects (91).
Linoleic acid is an omega-6 polyunsaturated fatty acid (PUFA) that is a constituent of 
vegetable oils. Because linoleic acid is a precursor of arachadonic acid, which gives rise to 
prostaglandins and inflammation, high intake of vegetable oils can alter the omega-6 to 
omega-3 ratio and be deleterious. However, certain gut microbiota, including strains of 
Lactobacilli and Bifidobacteria used in probiotics, can conjugate linoleic acid (91). Not only 
does this bacterial conjugation diminish linoleic acid levels, but some conjugated linoleic 
acid isomers are reported to have anti-inflammatory and anti-carcinogenic properties.
Future of probiotics and prebiotics in cancer prevention and therapy
As our knowledge of bioactive food components and microbiota increases, it is likely that 
prebiotics and probiotics will play a bigger role in cancer prevention and anticancer therapy. 
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Prebiotics are defined as indigestible food ingredients that selectively stimulate the growth 
and/or activity of certain gut microbiota that confer a health benefit. Probiotics correspond to 
the consumption of live microbiota present in foods or dietary supplements that confer a 
health benefit. Perhaps the best-known example of probiotics involves Lactobacillus in 
yogurt for promoting general GI health and preventing lactose intolerance. Streptococci and 
Bifidobacteria in cheeses and other foods and drinks are also commonplace. FMTs can also 
be considered a probiotic and are noteworthy because of their tremendous success in treating 
otherwise lethal Clostridium difficile infections, which usually arise because antibiotics 
eliminated commensal bacteria that are capable of displacing or suppressing C. difficile. 
Although there is not much evidence for specific microbiota in cancer prevention or 
treatment, this is likely to change. The most immediate measurable progress will probably 
involve Bifidobacterium and Bacteroides such as B. fragilis as adjuvants for immunotherapy 
as discussed above (42, 43). Another interesting possibility for cancer prevention or therapy 
involves genetically modified microbiota that provide additional value or benefit. For 
example, Lactobacillus strains have been engineered to overexpress the antioxidant 
superoxide dismutase or an anti-inflammatory protein (91). However, because even normal 
strains Lactobacillus have a very minor and transient impact on the gut microbiome, it might 
be necessary to develop a strategy to select for these microbes in the gut similar to the 
proposed gene-drive systems being utilized for sexually reproducing species such as 
mosquitoes in the case of malaria. In this regard, it is possible that CRISPR might be 
utilized, and this should be relatively efficient because most bacteria produce their own Cas9 
so it does not need to be delivered exogenously. If successful, engineered microbiota could 
add to the fast-growing functional food/nutraceutical industry.
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Figure 1. 
Gut microbiota influence CRC by multiple mechanisms. Schematic of colon showing 3 
compartments: top, the lumen containing dietary/digestive components (black), microbiota 
(gray), and metabolites (colors); middle, a single layer of epithelial cells; bottom, an 
underlying lamina propria containing immune cells. Gut bacteria can promote CRC by 
metabolizing oncogenic dietary/digestive components such as meat and bile acids into 
oncometabolites such as secondary bile acids (e.g., DCA) and hydrogen sulfide. Conversely, 
gut bacteria can protect against CRC by metabolizing beneficial dietary/digestive 
components such as plant-based polyphenols and fiber into tumor-suppressive metabolites 
such as butyrate. Bacteria (and their metabolites and antigens) can have direct effects on 
normal or cancerous colonocytes (left arrow) or influence immune cell activation and 
inflammation, which can occur directly (right arrow) or by maintaining colonocyte 
permeability and barrier function of the epithelium (middle arrow).
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Figure 2. 
Mechanism of fiber- and butyrate-mediated tumor suppression. Insoluble fiber speeds 
colonic transit to minimize carciongen exposure, while soluble fiber is fermented by gut 
bacteria into butyrate (left). In normal colonocytes (right, top), butyrate is utilized as the 
primary energy source to maintain homeostasis. Because it is readily metabolized in the 
mitochondria via fatty acid oxidation, relatively little accumulates inside the nucleus. In 
cancerous colonocytes (right, bottom), glucose is the primary energy source due to the 
Warburg effect. Butyrate is still transported into the cell via monocarboxylate transporters 
but is not metabolized in the mitochondria, which allows it to accumulate in the nucleus and 
function as an HDAC inhibitor to epigenetically regulate genes involved in cell proliferation 
and apoptosis.
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Figure 3. 
Dietary fiber protects against colorectal cancer in a microbiota- and butyrate-dependent 
manner in a gnotobiotic mouse model. Mice were colonized with several bacteria that either 
excluded or included a butyrate producer as indicated at the top. A wild-type and mutant 
strain of the butyrate producer was utilized in separate gnotobiotic isolators (depicted by 
boxes around each group of mice). In each isolator, the mice received control or high-fiber 
diets (6% fructo-oligosaccharides/inulin but otherwise virtually identical to the control diet) 
except for a butyrate-fortified diet in the isolator at the far right. Arrows at the bottom 
indicate relative levels of luminal butyrate along with global histone acetylation levels and 
tumor burden after tumorigenesis was initiated 5 months earlier. Butyrate production was 
attenuated, but not completely abolished, in the mutant strain when provided a high-fiber 
diet as denoted by one upward butyrate arrow instead of a downward arrow or two upward 
arrows. The yellow ovals highlight experimental conditions that yield a lower tumor burden, 
and this correlates with higher butyrate levels and histone acetylation levels.
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Table 1
Dietary and lifestyle factors that influence CRC risk.
Strength of Evidence Increased CRC Risk Decreased CRC Risk
Probable or Convincing Red meat
Processed meat
Alcoholic drinks
Obesity
Physical activity
Dietary fiber
Garlic
Milk
Calcium
Suggestive Foods containing iron
Cheese
Foods containining animal fats
Foods containing sugars
Nonstarchy vegetables
Fruits
Fish
Foods containing folate
Foods containing selenium
Foods containing vitamin D
Selenium
Inconclusive Cereals (grains) and their products; potatoes; poultry; shellfish and other seafood; other dairy products; total fat; 
fatty acid composition; cholesterol; sugar (sucrose); coffee; tea; caffeine; total carbohydrate; starch; vitamin A; 
retinol; vitamin C; vitamin E; multivitamins; non-dairy sources of calcium; methionine; beta-carotene; alpha-
carotene; lycopene; meal frequency; energy intake
Adapted from American Institute of Cancer (AICR) 2nd Annual Expert Report (5)
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